Information relating to the Extraordinary General Meeting of Diamyd Medical on April 22 regarding the proposed restructuring of the Diamyd Group

Provided that the Extraordinary General Meeting of Diamyd Medical AB to be held
on April 22 resolves in favor of the proposed restructuring of the Diamyd Group,
after which Diamyd Medical AB will be renamed Mertiva AB, the incoming Board of
Directors in the future Mertiva AB plans to appoint Andreas Bergsten as the
President at a statutory meeting following the General Meeting. The proposed
restructuring entails, among other effects, that the subsidiary Diamyd
Therapeutics AB will be distributed to shareholders and the intention is to list
the company on NASDAQ OMX First North. The current President of Diamyd Medical
AB, Peter Zerhouni, will remain as President of Diamyd Therapeutics AB.
Background to the restructuring
As previously announced in press releases issued on February 18 and March 21,
2013, the summons to an Extraordinary General Meeting was brought about due to
an agreement reached by a group of shareholders in Diamyd Medical AB who
together represent a majority of the votes and share capital in the company. The
agreement entails, among other factors, that the shares in the subsidiary Diamyd
Therapeutics AB, which will be capitalized at approximately SEK 50 million and
own the existing diabetes operations and the holding in Periphagen, Inc., will
be distributed to shareholders. The company will be renamed Diamyd Medical AB.
At the same time, the Parent Company will be renamed Mertiva AB. Liquid assets
of more than SEK 300 million and the holdings in Protein Sciences Corporation
and Mercodia AB will remain in Mertiva AB. The greater part of the liquid assets
in Mertiva AB is proposed to be distributed to the shareholders as soon as
possible.

Change of President in Diamyd Medical (future Mertiva)
The incoming Board of Directors of the future Mertiva AB plans to appoint
Andreas Bergsten as President in a statutory Board meeting following the
Extraordinary General Meeting to be held on April 22.

Andreas Bergsten, born in 1967, is currently working as a consultant in the
fields of finance and company management and, in his capacity as a consultant,
has worked primarily for venture capital firms. In the past, Andreas has served
as CFO of four different companies and, prior to this, he was employed at
Citigroup, initially as a financial analyst and subsequently as a key account
manager. Andreas holds a Master of Science in Business and Economics from the
Stockholm School of Economics and the McGill University MBA Program.

The incoming Board of Directors of the future Mertiva AB intends to bring up the
issue of moving the company’s listing from NASDAQ OMX Nordic Stockholm to
another, unregulated marketplace.

Redemption procedure in Diamyd Medical (future Mertiva) and distribution in kind
of Diamyd Therapeutics
As previously announced, the distribution of liquid assets in the future Mertiva
AB is proposed to take place by distributing non-restricted equity through
voluntary redemption of shares. Shareholders will receive one redemption right
per share held and five redemption rights entitle the shareholder to request
redemption of one share in the company. For each share redeemed, the shareholder
will receive cash payment of SEK 20. The Board of Directors also proposes that
the General Meeting approve a dividend in the form of all shares in the wholly
owned subsidiary Diamyd Therapeutics AB, whereby three Series A shares in the
future Mertiva AB will carry entitlement to one Series A share in the subsidiary
and three Series B shares in the future Mertiva AB will carry entitlement to one
Series B share in the subsidiary.

Summary of timetable for the redemption procedure and distribution in kind of
Diamyd Therapeutics
April 22, 2013
Extraordinary General Meeting in Diamyd Medical. Final day for trading in the
Diamyd share, including redemption rights and entitlement to distribution in
kind

April 23, 2013
First day of trading in the Diamyd share, excluding redemption rights and
entitlement to distribution in kind

April 25, 2013
Record date for receiving redemption rights and entitlement to distribution in
kind

April 30 – May 21, 2013
Period of registration to request redemption

April 30 – May 16, 2013
Trading in redemption rights on NASDAQ OMX Stockholm

Around June 14, 2013
Payment of redemption proceeds

Listing of Diamyd Therapeutics (future Diamyd Medical) on NASDAQ OMX First North
As announced earlier, the intention is to make the shares in Diamyd Therapeutics
AB available for trading on NASDAQ OMX First North. The first day of trading is
expected to be in mid-May 2013. Diamyd Therapeutics AB will be renamed Diamyd
Medical AB at the same time as the current Diamyd Medical AB will be renamed
Mertiva AB.

Peter Zerhouni, the current President of Diamyd Medical AB (future Mertiva AB)
will remain in his position as President of Diamyd Therapeutics AB (future
Diamyd Medical AB).

The Board of Directors of Diamyd Therapeutics AB (future Diamyd Medical AB) will
initially comprise Anders Essen-Möller (Chairman of the Board), Maria-Teresa
Essen-Möller and Erik Nerpin. All of these individuals are currently Board
members of Diamyd Medical AB.
For more information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of pharmaceutical
development. Diamyd Medical is headquartered in Stockholm, Sweden. The Company’s
development project consists of the protein GAD for the treatment and prevention
of autoimmune diabetes. Two Swedish researcher-initiated Phase II studies are
ongoing. One study evaluates whether GAD can prevent type 1 diabetes in children
who are at high risk of developing the disease and one study evaluates whether
GAD in combination with relatively high doses of vitamin D and ibuprofen can
preserve the body's own ability to control the blood sugar level in children and
adolescents newly diagnosed with type 1 diabetes.

Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA) and
the diagnostics company Mercodia AB (Sweden).

Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm (ticker:
DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC
Markets and the Bank of New York Mellon (PAL). Further information is available
on the Company’s website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities Markets
Act, the Swedish Financial Instruments Trading Act, or the requirements stated
in the listing agreements.

Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no: 556530-1420